Literature DB >> 21931023

Out-of-pocket costs for accessing adjuvant radiotherapy among Canadian women with breast cancer.

Sophie Lauzier1, Pascale Levesque, Mélanie Drolet, Douglas Coyle, Jacques Brisson, Benoît Mâsse, André Robidoux, Jean Robert, Elizabeth Maunsell.   

Abstract

PURPOSE: Patients with breast cancer incur out-of-pocket costs when they receive adjuvant radiation. These treatments are administered in dedicated centers on a daily basis over 4 to 5 weeks. We assessed the extent of out-of-pocket costs to access radiotherapy and identified women at risk of experiencing higher costs. PATIENTS AND METHODS: This prospective study was conducted among 800 women from eight Quebec hospitals (participation, 86%), of whom 693 women received adjuvant radiotherapy. Costs to access treatment (transportation, parking, lodging, and meals) were estimated on the basis of information collected by telephone interviews. Generalized linear models were used to identify women at risk of having higher costs.
RESULTS: Mean and median total costs (including financial aid received) to access radiotherapy were 445 Canadian dollars (Can$; standard deviation, Can$407) and Can$311, respectively. Women who lived at home but far from the radiotherapy center had the highest risk of experiencing weekly costs of at least Can$122 (highest quartile; prevalence ratio [PR], 5.8; 95% CI, 4.7 to 7.1) followed by women who lived away from home and farther from the center (PR, 4.5; 95% CI, 3.4 to 6.0) and by women who lived away from home and closer to the center (PR, 2.14; 95% CI, 1.3 to 3.5). When women stayed at a cancer lodge during treatment, costs were reduced by 80%.
CONCLUSION: Considered in and of themselves, out-of-pocket costs for access to radiotherapy appeared relatively modest. Financial assistance initiatives for women who lived away from home during treatments contributed to a substantial reduction of access costs. These efforts should be maintained, but financial assistance should also target patients with cancer who live at home during treatments but have to travel relatively long distances on a daily basis.

Entities:  

Mesh:

Year:  2011        PMID: 21931023     DOI: 10.1200/JCO.2011.35.1007

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  10 in total

1.  Pre-diagnosis employment status and financial circumstances predict cancer-related financial stress and strain among breast and prostate cancer survivors.

Authors:  Linda Sharp; Aileen Timmons
Journal:  Support Care Cancer       Date:  2015-07-05       Impact factor: 3.603

2.  The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.

Authors:  S Yousuf Zafar; Jeffrey M Peppercorn; Deborah Schrag; Donald H Taylor; Amy M Goetzinger; Xiaoyin Zhong; Amy P Abernethy
Journal:  Oncologist       Date:  2013-02-26

3.  Responses by breast and prostate cancer patients to out-of-pocket costs in Newfoundland and Labrador.

Authors:  E Housser; M Mathews; J Lemessurier; S Young; J Hawboldt; R West
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

4.  Financial toxicity associated with a cancer diagnosis in publicly funded healthcare countries: a systematic review.

Authors:  Christopher J Longo; Margaret I Fitch; Laura Banfield; Paul Hanly; K Robin Yabroff; Linda Sharp
Journal:  Support Care Cancer       Date:  2020-07-11       Impact factor: 3.603

Review 5.  The global impact of non-communicable diseases on households and impoverishment: a systematic review.

Authors:  Loes Jaspers; Veronica Colpani; Layal Chaker; Sven J van der Lee; Taulant Muka; David Imo; Shanthi Mendis; Rajiv Chowdhury; Wichor M Bramer; Abby Falla; Raha Pazoki; Oscar H Franco
Journal:  Eur J Epidemiol       Date:  2014-12-21       Impact factor: 8.082

6.  HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ.

Authors:  E Rakovitch; S Nofech-Mozes; W Hanna; S Narod; D Thiruchelvam; R Saskin; J Spayne; C Taylor; L Paszat
Journal:  Br J Cancer       Date:  2012-02-23       Impact factor: 7.640

7.  Patient and family financial burden associated with cancer treatment in Canada: a national study.

Authors:  Christopher J Longo; Margaret I Fitch; Jonathan M Loree; Linda E Carlson; Donna Turner; Winson Y Cheung; Darin Gopaul; Janet Ellis; Jolie Ringash; Maria Mathews; Jim Wright; Christiaan Stevens; David D'Souza; Robin Urquhart; Tuhin Maity; Fanor Balderrama; Evette Haddad
Journal:  Support Care Cancer       Date:  2021-01-05       Impact factor: 3.603

8.  Cost-effectiveness of Nivolumab-Ipilimumab Combination Therapy for the Treatment of Advanced Non-Small Cell Lung Cancer.

Authors:  P Travis Courtney; Anthony T Yip; Daniel R Cherry; Mia A Salans; Abhishek Kumar; James D Murphy
Journal:  JAMA Netw Open       Date:  2021-05-03

9.  Cost-effectiveness of ipilimumab versus high-dose interferon as an adjuvant therapy in resected high-risk melanoma.

Authors:  Mia Salans; Patrick Travis Courtney; Anthony Yip; James D Murphy
Journal:  Cancer Med       Date:  2021-08-17       Impact factor: 4.452

10.  Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.

Authors:  Yan Li; Xueyan Liang; Tong Yang; Sitong Guo; Xiaoyu Chen
Journal:  Front Oncol       Date:  2022-09-26       Impact factor: 5.738

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.